This observational study aims to evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) alone in patients with stage IB nasopharyngeal carcinoma (NPC) without high-risk features. The primary objective is to determine the therapeutic effectiveness of this approach
Study Type
OBSERVATIONAL
Enrollment
169
All patients administered with definitive radiotherapy
Fujian Cancer Hospital
Fuzhou, Fujian, China
RECRUITINGRelapse-Free Survival
Time from diagnosis to the disease relapse (either locoregional recurrence or distant metastasis) or death from any cause.
Time frame: 3-year
Locoregional Relapse-Free Survival
Time from diagnosis to first documented locoregional recurrence before the last follow-up visit.
Time frame: 3-year
Distant Metastasis-Free Survival
Time from diagnosis to first documented distant metastasis before the last follow-up visit
Time frame: 3-year
Overall Survival
Time from diagnosis to death from any cause or to the last follow-up visit for patients still alive.
Time frame: 3-year
Safety of Radiation
Acute and late radiation toxicities were graded with the CTCAE criteria
Time frame: at inclusion, 3 months, 6 months,12 months, 24 months, 36 months, and 60 months
Quality of life (EORTC QLQ C30)
Quality of life score was calculated according to the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ C30), the range is 0-100, higher scores mean a worse outcome.
Time frame: at inclusion, 3 months, 6 months,12 months, 24 months, 36 months, and 60 months.
Quality of life score QLQ-HN35
The quality of life score was calculated according to the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire QLQ-HN35; the range is 0-100, with higher scores indicating a worse outcome.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: at inclusion, 3 months, 6 months,12 months, 24 months, 36 months, and 60 months.